OncLive TV

Healthcare Reform

Disparities in the Healthcare System

Dr. Howard Sandler from Cedars-Sinai Medical Center discusses the TAK-700 in Localized Prostate Cancer Clinical Trials

Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom on the Value of the Negative Iniparib Trial Results

Robert Dreicer, MD, from the Taussig Cancer Institute, Discusses How New Treatments Have Improved Survival

In an interview at the 2011 IPCC Meeting in New York, Leonard G. Gomella, MD, from Jefferson Kimmel Cancer Center, discusses prostate cancer screening procedures.

Howard M. Sandler, MD, MS from Cedars-Sinai Medical Center, on Guideline Compliant Care

Robert Dreicer, MD, from the Taussig Cancer Institute, discusses the various treatments that prostate cancer patients may receive in combination.

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, discusses candidates for liase inhibitor clinical trials.

Howard M. Sandler, MD, MS, from Cedars-Sinai Medical Center, compares the efficacy of the mechanism of action for traditional LHRH agonists to newer androgen deprivation therapies

Daniel P. Petrylak, MD, from Columbia University Medical Center Explains the Difficulties Facing During Prostate Cancer Clinical Trials

Mark G. Kris, MD. Chief, Thoracic Oncology Service at Memorial Sloan-Kettering Cancer Center in New York on the EML4-ALK Translocation